RPE65 and Dyschromatopsia: However, previous pharmacological strategies targetingretinoid isomerization of RPE65 were unsuccessful, mostly due to theinability to achieve a balance between beneficial and adverse effectsof therapies.45 To minimize the side effects,such as night blindness and dyschromatopsia, associated with the directblockage of 11cRAL production by RPE65 inhibitors, alternative strategieswere developed.